Novo Nordisk A/SNVONYSE
Loading
Debt Growth Recovery in ProgressRecovering
Percentile Rank67
3Y CAGR-64.4%
5Y CAGR-29.0%
Year-over-Year Change
Year-over-year debt growth rate
3Y CAGR
-64.4%/yr
vs +446.3%/yr prior
5Y CAGR
-29.0%/yr
Recent deceleration
Acceleration
-510.7pp
Decelerating
Percentile
P67
Within normal range
vs 5Y Ago
0.2x
Contraction
Streak
2 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 29.39% |
| Q3 2025 | 1.96% |
| Q2 2025 | -16.39% |
| Q1 2025 | 15.50% |
| Q4 2024 | 80.42% |
| Q3 2024 | 594.75% |
| Q2 2024 | -69.55% |
| Q1 2024 | -0.29% |
| Q4 2023 | 616.77% |
| Q3 2023 | 0.04% |
| Q2 2023 | 1.20% |
| Q1 2023 | -85.57% |
| Q4 2022 | 653.58% |
| Q3 2022 | -4.31% |
| Q2 2022 | -6.19% |
| Q1 2022 | -85.70% |
| Q4 2021 | 1143.50% |
| Q3 2021 | -2.38% |
| Q2 2021 | 43.86% |
| Q1 2021 | -10.37% |
| Q4 2020 | 163.30% |
| Q3 2020 | 3.56% |
| Q2 2020 | 3.31% |
| Q1 2020 | -10.26% |
| Q4 2019 | -84.49% |
| Q3 2019 | 2.62% |
| Q2 2019 | -1.99% |
| Q1 2019 | 738.45% |
| Q4 2018 | 52.82% |
| Q3 2018 | 36.44% |
| Q2 2018 | 8.33% |
| Q1 2018 | -86.54% |
| Q4 2017 | 551.54% |
| Q3 2017 | -84.55% |
| Q2 2017 | 174.55% |
| Q1 2017 | 167.69% |
| Q4 2016 | -49.78% |
| Q3 2016 | 12.32% |
| Q2 2016 | 0.00% |
| Q1 2016 | -62.16% |